An Australian Multicentre Double-Blinded Randomised Controlled Trial of Genotype-guided versus Standard Psychotropic Therapy in Moderately-to-Severely Depressed Patients Initiating Pharmacotherapy- ALIGNED

This proposal addresses the desired outcomes of the grant opportunity, including: reduce barriers to clinical uptake of pharmacogenomics (PG), by conducting a robust randomised controlled trial (RCT) to close evidence gaps; and by partnering with health services and consumer advocacy group to develop practice guidelines, treatment protocols, and a user-friendly PG support tool close gaps in evidence related to PG application, by conducting the first non-biased, doubleblinded, well-powered RCT, using highly evidence-based combinatorial PG, and incorporating comprehensive economic evaluation, focusing on treatment-nave patients, the cohort where there is relative paucity of evidence combine new (PG) and existing (neuroimaging) technology with scalable data, via application of deep learning to combine multimodal data generated from this proposal, as well as our previous data, to refine and improve the precision of psychotropic therapy for depression.